Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lexagene Holdings Inc LXXGQ

Lexagene Holdings Inc. is a molecular diagnostics company engaged in researching, developing and commercializing automated genetic analyzer devices in clinical and life science industries. The Company is focused on developing molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The Company's MiQLab System is an automated, open-access molecular diagnostic system for pathogen detection, allowing users to test for multiple pathogens onsite, returning results in approximately 2 hours. Its MiQLab System is an automated, multiplexing polymerase chain reaction (PCR)-based system designed for syndromic testing in human clinical diagnostics and veterinary diagnostics, as well as food safety testing, and open-access custom testing markets.


GREY:LXXGQ - Post by User

Post by Chopper1BigDogon Mar 01, 2021 8:48am
167 Views
Post# 32683983

Lex

Lex Reminder of just how big Lexagene will be! LexaGene’s MiQLab™ system is designed to respond to multi-billion dollar markets in need of rapid automated pathogen detection and customized testing.
 

Human Clinical Diagnostics
• COVID-19 testing $5.2 Billion USD market
• Rapid qPCR testing needed
• PCR testing considered the gold-standard of testing
• $12.9 billion USD by 2025
> Learn more

Veterinary Diagnostics
• Companion animal diagnostics
• Infections and antibiotic resistance can be quickly detected so the appropriate antibiotic is prescribed
• Reference laboratory accounts for largest market share of the veterinary diagnostics market
• North America accounts for largest segment due to well-established animal healthcare market
• $2.2 billion USD Market by 2024
> Learn more

Food Safety Testing
• 1.1 B tests performed per year
• Mandatory food testing now required
• Prevents costly recalls, brand damage
• Fresher, safer product to customer (eliminates 2-day hold on food)
• Hundreds of food recalls in the US each year
• Major disease-causing pathogen: Salmonella/E. coli
• $23.4 Billion USD market by 2024
> Learn more

Open-Access Markets
$20 Billion USD markets:
• Labs looking for automation and customization
• Pharma, biotech, academic labs – (18,000 moderate complexity CLIA labs in the US)
• PCR market – $4.33B USD by 2026
• Genotyping – $11.8B USD
Other open-access markets:
• Water Quality Monitoring – $1.59B USD by 2022
• Agricultural Testing – $6.29B USD by 2022
• Aquaculture Bacterial Testing
> Learn more

Pandemic Prevention
Threat of next outbreak or pandemic is real
• LexaGene technology ideally suited to contain outbreaks
• Need rapid time to results for quarantine decisions
• Test at point-of-need required (hospitals, clinics, institutions)
• Need tests that can be easily deployed
• Require reagents that are easy to manufacture for worldwide coverage
• Current testing methods don’t meet the needs

More Markets
LexaGene’s technology has a wide range of applications across other markets at point-of-need:
• Cruise ships
• Biodefense
• Military bases and aircraft carriers
• Etc.
<< Previous
Bullboard Posts
Next >>